Zambon Pharma
Zambon Pharma is a privately held, family-owned Italian pharmaceutical multinational founded in 1906 that develops and commercializes branded therapeutics in severe respiratory diseases, CNS disorders, pain, and women's health across 87 countries, with four manufacturing plants and a global CDMO business.
- Company typePrivate
- Founded1906
- HeadquartersMilano, Italy
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Zambon Pharma does
Zambon Pharma is a privately held, family-owned Italian pharmaceutical multinational founded in 1906 and headquartered in Bresso (Milan), with reported group revenue of 899 million euros and a workforce of approximately 2,768 employees across 15 countries. The company develops, manufactures, and commercializes branded pharmaceutical products in four primary therapeutic areas: severe respiratory diseases (Bronchiolitis Obliterans Syndrome, non-cystic fibrosis bronchiectasis, and cystic fibrosis via inhaled liposomal cyclosporine and Fluimucil/N-acetylcysteine), central nervous system disorders (Parkinson's disease through IPX203 licensed from Amneal, and ALS via the Aquestive partnership), pain management, and women's health (urinary tract infections). Its core technology spans sterile injectables, oral solids, lyophilized products, and liposomal inhalation formulations manufactured across four owned plants in Italy (Vicenza), Switzerland (Cadempino), China (Haikou), and Brazil (Barueri), supplemented by a Virtual Plant network coordinating 27 contract manufacturers globally.
The business operates a hybrid revenue model combining branded pharmaceutical sales (direct field sales forces targeting hospitals, specialists, and pharmacies across 87 countries), CDMO services for third-party pharmaceutical companies, and API/custom synthesis through the Zach System subsidiary. Distribution channels include direct enterprise sales, pharmacy distribution, hospital tenders, and B2B contract manufacturing relationships. Supporting the core pharma business, Zambon operates Zcube (a research venture running the Open Accelerator startup program), OpenZone (a scientific campus housing the new Z-LIFE headquarters), and Fondazione Zoé (health education). The company is led by Elena Zambon as President, with recent executive additions including a Chief Core Therapies Officer and Chief HR Officer in 2025, reflecting organizational alignment around therapeutic-area-focused growth and continued internationalization, particularly into China where Zambon secured regulatory approval and launched Fluimucil IV in June 2025.
Zambon Pharma firmographics
Firmographics- Name
- Zambon Pharma
- Legal name
- Zambon S.p.A.
- Website
- https://zambon.com
- Company type
- Private
- Founded year
- 1906
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Zambon Pharma is a privately held, family-owned Italian pharmaceutical multinational founded in 1906 that develops and commercializes branded therapeutics in severe respiratory diseases, CNS disorders, pain, and women's health across 87 countries, with four manufacturing plants and a global CDMO business.
- Ownership category
- akta.pro rank
Zambon Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule API & Intermediates CDMO (HLAGABAA)
Keywords
Where Zambon Pharma is headquartered
LocationHeadquarters
- HQ city
- Milano
- HQ country
- Italy
- HQ region
- Europe
Offices6 records
Markets served
Zambon Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Products: Revenue from branded pharmaceutical products for severe respiratory diseases, respiratory diseases, pain, CNS disorders (Parkinson's, ALS), and women's health (urinary tract infections). Products include Fluimucil (N-acetylcysteine), treatments for cystic fibrosis, BOS, and NCFB.
- CDMO Services: Contract manufacturing organization providing pharmaceutical development and manufacturing services to third-party pharmaceutical companies. Services span from formulation development through commercial production.
- Active Pharmaceutical Ingredients (Zach System): Production and custom synthesis of Active Pharmaceutical Ingredients (API) and advanced intermediates for the pharmaceutical industry through Zach System division.
- Virtual Plant / Toll Manufacturing: Management of outsourced production through network of 27 contract manufacturers globally, ensuring quality, supply continuity, and cost efficiency.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Zambon Pharma product offering
Product offeringCore offering
Zambon Pharma researches, develops, manufactures, and commercializes branded specialty pharmaceutical products across severe respiratory diseases (BOS, NCFB, cystic fibrosis), central nervous system disorders (Parkinson's disease, ALS), pain management, and women's health (urinary tract infections). The group also provides CDMO contract development and manufacturing services to third-party pharmaceutical companies, and through its Zach System division produces Active Pharmaceutical Ingredients and advanced intermediates. Core commercial products include Fluimucil (N-acetylcysteine), IPX203 (carbidopa/levodopa for Parkinson's), and inhaled liposomal cyclosporine for BOS.
Product overview
Zambon Pharma is a pharmaceutical multinational offering a diversified portfolio of therapeutic solutions across multiple specialty areas: severe respiratory diseases (BOS, NCFB, cystic fibrosis), neurological disorders (Parkinson's disease, ALS), pain management, and women's health (urinary tract infections). The core pharmaceutical business operates alongside supporting entities including Zach System (API manufacturing and custom synthesis), Zcube (digital health innovation and Open Accelerator program), and the OpenZone campus. Key products include Fluimucil (N-acetylcysteine respiratory therapy), IPX203 (Parkinson's carbidopa/levodopa formulation), and inhaled liposomal cyclosporine for BOS. The company also offers CDMO services through its manufacturing plants in Italy, Switzerland, China, and Brazil, plus a Virtual Plant network managing 27 contract manufacturers globally.
Differentiator
Problem solved
Functional benefit
Brands
- Z-Life: The new headquarters of Zambon Pharma, created within the OpenZone campus, designed to promote an approach based on sharing without borders and transforming ideas into tangible opportunities for patients.
- Benvivere
- Open Accelerator
- Zgen
- Zambon For Kids
- Zambon For Others
- Health & Quality Factory
- Fluimucil
- Zach System
Products and services
- Fluimucil (N-acetylcysteine) N-acetylcysteine-based therapeutic solution for respiratory conditions, available in multiple formulations including IV for severe cases, used to treat cough, cold, influenza, acute bronchitis, and COPD.
- IPX203 New oral formulation of carbidopa/levodopa for the treatment of Parkinson's disease, licensed exclusively from Amneal Pharmaceuticals for the EU, UK, and Switzerland markets.
- Inhaled Liposomal Cyclosporine Investigational formulation delivering elevated bronchiolar concentrations to halt progression of Bronchiolitis Obliterans Syndrome (BOS) following lung and hematopoietic stem cell transplantation.
- CDMO Contract Development and Manufacturing Services Contract Development and Manufacturing Organization services offering formulation studies, analytical method development and validation, clinical trial batches, scale-up, process validation, and stability studies. Capabilities span oral forms (tablets, coated tablets, granules, effervescent tablets, solutions, syrups, drops, ear drops, nasal sprays) and sterile forms (injectables, lyophilized products, vials, ampoules, sterile powder).
- Zach System API and Custom Synthesis Production and custom synthesis of Active Pharmaceutical Ingredients (API) and advanced intermediates for the pharmaceutical industry through the Zach System division, operated from an FDA-inspected multipurpose facility in Avrillé, France with reactors from 50L to 10,000L.
Quantifiable outcome
- 75% of lung transplant patients develop BOS within 10 years
- +4 more outcomes
Companies that use Zambon Pharma
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles2 records
Zambon Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Zambon Pharma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor and core.
- CultipharmminorCultipharm and Zambon announced a strategic agreement for the development of new advanced nutraceutical product lines, expanding into the health supplements market.
- Chinese Regulatory Authorities (sFDA)coreZambon obtained regulatory approval from China's sFDA (State Food and Drug Administration) and launched Fluimucil IV (N-acetylcysteine intravenous formulation) in China following a clinical development program conducted entirely in the country. This represents a significant market entry milestone.
- Amneal PharmaceuticalscoreZambon Biotech SA signed an exclusive license agreement with Amneal Pharmaceuticals for IPX203 - a new oral formulation of carbidopa/levodopa for Parkinson's disease treatment - covering European Union, United Kingdom, and Switzerland markets.
- AquestivecoreCollaboration with Aquestive for ALS (Amyotrophic Lateral Sclerosis) treatment formulation. Through this partnership, Zambon expanded its CNS portfolio with a new formulation that is now commercialized in some European countries, addressing orphan diseases and CNS therapeutic area.
- International Scientific CommunitycoreZambon strengthens collaborations with the international scientific community and representative patient groups through participation in international congresses and publication of clinical data in important journals. Global Medical Office R&D works to build a proprietary product pipeline with global presence.
- Other Italian Pharmaceutical Companies in ChinaminorItalian pharmaceutical companies including Chiesi, Bracco, and Recordati are mentioned as peers deepening strategic presence in China through local clinical trials, product launches, and manufacturing investments - context for competitive landscape rather than direct partnerships.
Scale indicators10 records
Recent moves7 records
Expansion highlights5 records
Zambon Pharma competitors and assessment
Company assessmentDirect peers
- Chiesi Farmaceutici: Italian family-owned multinational pharmaceutical company with a strong respiratory focus (similar to Zambon's severe respiratory franchise) and comparable mid-size private scale. Operates globally with branded specialty pharma and CDMO operations, making it the closest direct analog to Zambon in therapeutic focus, ownership structure, and geographic reach.
- Menarini Group: Italian privately-held pharmaceutical group of similar scale and heritage, operating across specialty therapeutics with global commercialization. Comparable in family/private ownership, European HQ, multi-country manufacturing, and broad therapeutic area coverage including specialty and consumer health segments.
- Recordati: Italian specialty pharmaceutical company listed on the Milan Stock Exchange, focused on rare diseases, CNS, and specialty therapeutics. Comparable therapeutic mix (CNS/specialty) and Italian heritage; serves as a useful listed-comp valuation reference for Zambon's specialty pharma franchise.
- Angelini Industries: Italian privately-held diversified group with a significant pharmaceutical division (Angelini Pharma) operating across CNS, pain, and consumer health. Comparable in private family ownership, Italian heritage, mid-size European scale, and presence across similar therapeutic categories including pain and women's health.
- H. Lundbeck: Danish specialty pharmaceutical company with a CNS-focused franchise (similar to Zambon's Parkinson's and ALS investments). Comparable mid-cap specialty pharma profile with concentrated CNS therapeutic focus and similar revenue band.
- Ipsen: French specialty pharmaceutical company with strong CNS, oncology, and rare-disease franchises. Comparable mid-cap European specialty pharma profile with focus on high-unmet-need therapeutic areas, similar to Zambon's severe respiratory and CNS positioning.
Broad incumbents
- Almirall: Spanish listed specialty pharmaceutical company focused on dermatology and specialty therapeutics, with European-wide commercialization. Comparable in mid-cap specialty pharma scale and European geographic footprint, though more concentrated in dermatology rather than CNS/respiratory.
- UCB: Belgian specialty pharmaceutical company with a strong CNS franchise (epilepsy, Parkinson's) and immunology focus. Comparable in CNS therapeutic overlap (notably Parkinson's) and European specialty pharma positioning, though UCB is a substantially larger publicly-listed company.
- Catalent: Global CDMO serving the pharmaceutical industry across drug substance, drug product, and clinical supply. Comparable to Zambon's CDMO/Virtual Plant and Zach System API operations as a peer for benchmarking contract manufacturing scale, capabilities, and margins.
Emerging players
- Jazz Pharmaceuticals: Irish/US specialty pharmaceutical company with a CNS and rare-disease franchise (narcolepsy, epilepsy, oncology). Comparable in CNS specialty focus and rare-disease commercial model, though more US-centric and listed, providing a useful reference for Zambon's CNS commercialization economics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Zambon Pharma social profiles
Digital presenceZambon Pharma compliance and trust
Trust signalCompliance10 records
Zambon Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Zambon Pharma leadership team
Management profileNumber of profiles
Profiles7 records
Zambon Pharma subsidiaries and ownership
Company hierarchySubsidiaries6 records
Zambon Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Zambon Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Zambon Pharma
What does Zambon Pharma do?
Zambon Pharma researches, develops, manufactures, and commercializes branded specialty pharmaceutical products across severe respiratory diseases (BOS, NCFB, cystic fibrosis), central nervous system disorders (Parkinson's disease, ALS), pain management, and women's health (urinary tract infections). The group also provides CDMO contract development and manufacturing services to third-party pharmaceutical companies, and through its Zach System division produces Active Pharmaceutical Ingredients and advanced intermediates. Core commercial products include Fluimucil (N-acetylcysteine), IPX203 (carbidopa/levodopa for Parkinson's), and inhaled liposomal cyclosporine for BOS.
Is Zambon Pharma a public or private company?
Zambon Pharma is a private company. It is classified as family owned and is currently operating.
When was Zambon Pharma founded?
Zambon Pharma was founded in 1906. It employs 1,001 to 5,000 people.
Where is Zambon Pharma based?
Zambon Pharma is headquartered in Milano, Italy, in the Europe region.
How does Zambon Pharma make money?
Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are CDMO Services, active Pharmaceutical Ingredients (Zach System) and virtual Plant / Toll Manufacturing.
Who are Zambon Pharma's main competitors?
Direct peers on record are Chiesi Farmaceutici, Menarini Group, Recordati, Angelini Industries, H. Lundbeck and Ipsen. Broad incumbents are Almirall, UCB and Catalent. Jazz Pharmaceuticals is listed as an emerging player.
Does Zambon Pharma have an API?
No public API is recorded for Zambon Pharma.
What industry is Zambon Pharma in?
Zambon Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.